A detailed history of Jfs Wealth Advisors, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jfs Wealth Advisors, LLC holds 2 shares of NTLA stock, worth $30. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 11 81.82%
Holding current value
$30
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$19.72 - $27.36 $177 - $246
-9 Reduced 81.82%
2 $0
Q4 2023

Feb 07, 2024

BUY
$23.16 - $32.34 $254 - $355
11 New
11 $0
Q1 2022

May 02, 2022

SELL
$58.27 - $118.99 $116 - $237
-2 Closed
0 $0
Q4 2021

Feb 03, 2022

BUY
$100.76 - $138.36 $201 - $276
2 New
2 $0
Q4 2020

Feb 01, 2021

SELL
$18.83 - $63.53 $3,389 - $11,435
-180 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$11.14 - $22.87 $2,005 - $4,116
180 New
180 $4,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.15B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jfs Wealth Advisors, LLC Portfolio

Follow Jfs Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.